Lebed.biz Alert – SCLL could’ve prevented Hydroxycut recall!
May 22nd, 2009 by beststockreport
Hydroxycut was just recalled by the FDA after 9 million packages were sold last year! How come? It caused liver damage!
I bet the millions of people taking it thought it was a supplement that came from a plant and there was no way it could cause liver damage! Guess what… these supplements are sometimes the most toxic to the liver as the most potent chemicals ever identified are plant products!
Often supplement products go through no real liver toxicity testing at all, and other times drugs in Phase I trials fail due to liver toxicity that could’ve been discovered early on in the drug development process before the pharma wasted hundreds of millions of dollars.
SCLL’s ACTIVTox testing system could help prevent recalls associated with liver toxicity and help phamas discover liver toxicity problems early on!
ACTIVTox is a series of in vitro toxicology assays that accurately predict the liver’s response to new drug compounds and is built around SCLL’s patented C3A human liver cell line, which possesses the functions of an adult liver cell.
ACTIVTox produces liver-specific proteins such as apolipoprotein and albumin, and exhibits Phase II metabolism as well as the appropriate p450 enzymes. The ACTIVTox cells are robust, reproducible, and adaptable to high-throughput assays. These features make ACTIVTox an excellent tool for studying human liver biology.
SCLL has developed a predictive database called PREDICTIVTox of structured toxicity information comprising thousands of compounds that have been fully profiled using ACTIVTox. The broad hepatotoxicity database acts as a guide to synthesize new compounds while minimizing toxic liabilities.
In my opinion, SCLL’s ACTIVTox and PREDICTIVTox coupled together could potentially revolutionize the way major pharmas examine toxicity early in the drug development!
It is unbelievable to me SCLL is trading for less than a penny when this is one of the only stem cell companies with a viable product! Read the press release SCLL just issued this morning about the Hydroxycut issue: http://finance.yahoo.com/news/ FDAs-Hydroxycut-Recall-prnews- 15314345.html
—–
My firm Lebed Biz LLC has been compensated by SCLL $15,000 cash for a one-month investor relations contract. Never invest into a stock we discuss unless you can afford to lose your entire investment. For our full disclaimer go to: www.lebed.biz/disclaimer.htm
Jonathan Lebed
Lebed.biz
Staff